Capital Analysts LLC Portfolio holdings
Capital Analysts is a Lincoln Investment company that provides a ready-made wealth management platform to independent financial professionals who serve affluent clients. Capital Analysts dates from 2012 and belongs to Lincoln Investment Capital Holdings; Lincoln Investment Planning, a brokerage and advisory firm under the same ownership, handles brokerage services for it and its advisors. Those advisors work across the United States as independent contractors, not employees. Their clients include individuals, high net worth individuals, trusts, foundations, businesses and charities, and Capital Analysts also offers its institutional advisory services to other advisers and trust companies. The portfolios it builds aim to be diversified and rest on asset allocation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity Enhanced Small Cap Core ETF
FESM
|
+$99.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$18M |
| 3 |
Harbor Commodity All-Weather Strategy ETF
HGER
|
+$15.7M |
| 4 |
iShares Core Universal USD Bond ETF
IUSB
|
+$14.4M |
| 5 |
State Street SPDR Portfolio S&P 500 ETF
SPYM
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Portfolio Intermediate Term Corporate Bond Index ETF
SPIB
|
+$21.3M |
| 2 |
iShares S&P 100 ETF
OEF
|
+$10.7M |
| 3 |
Invesco S&P 500 Revenue ETF
RWL
|
+$10.1M |
| 4 |
iShares MBS ETF
MBB
|
+$6.31M |
| 5 |
iShares MSCI USA Momentum Factor ETF
MTUM
|
+$6.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 77.86% |
| 2 | Technology | 5.89% |
| 3 | Financials | 4.02% |
| 4 | Industrials | 2.27% |
| 5 | Healthcare | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1676
Medline Inc
MDLN
$34.7B
| $243 | ﹤0.01% |
+7
| New | +$256 |
2026 Q3
0 quarters
|
|
1677
Boot Barn
BOOT
$4.12B
| $241 | ﹤0.01% |
+2
| New | +$300 |
2026 Q3
0 quarters
|
|
1678
Tarsus Pharmaceuticals
TARS
$3.96B
| $236 | ﹤0.01% |
+3
| New | +$208 |
2026 Q3
0 quarters
|
|
1679
Graco
GGG
$11.6B
| $231 | ﹤0.01% |
+3
| New | +$234 |
2026 Q3
0 quarters
|
|
1680
Trump Media & Technology Group
DJT
$1.29B
| $227 | ﹤0.01% |
25
| – | – |
2025 Q2
5 quarters
|
|
1681
Acadia Realty Trust
AKR
$2.79B
| $225 | ﹤0.01% |
+12
| New | +$250 |
2026 Q3
0 quarters
|
|
1682
Atmus Filtration Technologies
ATMU
$4.49B
| $217 | ﹤0.01% |
+5
| New | +$246 |
2026 Q3
0 quarters
|
|
1683
Sterling Capital Funds
SCEC
$592M
| $214 | ﹤0.01% |
+9
| New | +$220 |
2026 Q3
0 quarters
|
|
1684
The Magnum Ice Cream Company N.V.
MICC
$12B
| $214 | ﹤0.01% |
12
| – | – |
2025 Q4
3 quarters
|
|
1685
Pathward Financial
CASH
$1.57B
| $213 | ﹤0.01% |
+3
| New | +$252 |
2026 Q3
0 quarters
|
|
1686
Republic Services
RSG
$77.1B
| $210 | ﹤0.01% |
1
| – | – |
2025 Q3
4 quarters
|
|
1687
Acadia Pharmaceuticals
ACAD
$3.24B
| $202 | ﹤0.01% |
+10
| New | +$268 |
2026 Q3
0 quarters
|
|
1688
Applied Optoelectronics
AAOI
$4.53B
| $199 | ﹤0.01% |
+2
| New | +$224 |
2026 Q3
0 quarters
|
|
1689
Credo Technology Group
CRDO
$24.7B
| $195 | ﹤0.01% |
1
-5
| -83% | -$1.08K |
2026 Q2
1 quarter
|
|
1690
Installed Building Products
IBP
$6.09B
| $192 | ﹤0.01% |
+1
| New | +$226 |
2026 Q3
0 quarters
|
|
1691
Fox Class A
FOXA
$28.9B
| $191 | ﹤0.01% |
3
| – | – |
2025 Q1
6 quarters
|
|
1692
EnerSys
ENS
$5.09B
| $184 | ﹤0.01% |
+1
| New | +$189 |
2026 Q3
0 quarters
|
|
1693
Brown & Brown
BRO
$23.9B
| $183 | ﹤0.01% |
+3
| New | +$206 |
2026 Q3
0 quarters
|
|
1694
Acadian Asset Management
AAMI
$3.35B
| $183 | ﹤0.01% |
+2
| New | +$176 |
2026 Q3
0 quarters
|
|
1695
Americold
COLD
$4.77B
| $182 | ﹤0.01% |
+13
| New | +$193 |
2026 Q3
0 quarters
|
|
1696
Spyre Therapeutics
SYRE
$9.9B
| $178 | ﹤0.01% |
+2
| New | +$192 |
2026 Q3
0 quarters
|
|
1697
Dianthus Therapeutics
DNTH
$5.17B
| $176 | ﹤0.01% |
+2
| New | +$208 |
2026 Q3
0 quarters
|
|
1698
National Healthcare Properties, Inc. Common Stock
NHP
$1.1B
| $176 | ﹤0.01% |
+11
| New | +$176 |
2026 Q3
0 quarters
|
|
1699
Eagle Materials
EXP
$5.5B
| $171 | ﹤0.01% |
+1
| New | +$200 |
2026 Q3
0 quarters
|
|
1700
Nurix Therapeutics
NRIX
$1.69B
| $166 | ﹤0.01% |
+7
| New | +$175 |
2026 Q3
0 quarters
|
|
Similar funds
Capital Analysts LLC's Q3 2026 Portfolio in Review
As of Q3 2026, Capital Analysts LLC held 1,773 positions worth $4.61B, up 6.1% from $4.34B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Capital Analysts LLC deployed $285M of net new capital in Q3 2026, opening 200 new positions and adding to 584 existing holdings. Its largest new stake was iShares MSCI ACWI ex US ETF: 126,684 shares worth $9.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 78% of assets, up from 77% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR Portfolio Intermediate Term Corporate Bond Index ETF, an estimated $21.3M trimmed.
- Capital Analysts LLC's largest Q3 2026 buy was iShares MSCI ACWI ex US ETF: 126,684 shares worth $9.6M.
- Capital Analysts LLC added most to Fidelity Enhanced Small Cap Core ETF in Q3 2026, an estimated $99.3M increase.
- Capital Analysts LLC's biggest Q3 2026 reduction was State Street SPDR Portfolio Intermediate Term Corporate Bond Index ETF, cutting an estimated $21.3M.
- Capital Analysts LLC fully exited Aecom in Q3 2026, selling an estimated $2.67M.
- Capital Analysts LLC's ten largest holdings make up 30% of its $4.61B portfolio in Q3 2026.
- Capital Analysts LLC opened 200 new positions and closed 51 in Q3 2026.
- Capital Analysts LLC's portfolio value rose 6.1% quarter-over-quarter to $4.61B.
Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.